Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

Stopped early · Phase 2

Conditions studied: Idiopathic Multicentric Castleman's Disease

In brief

Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD

Key facts

Study ID

NCT04838860

Run by

RECORDATI GROUP

People needed

22

Starts

2021-03-31

Expected to finish

2021-04-01

Last updated by the study team

2021-04-19

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented history of consensus histologic, laboratory, and clinical diagnostic criteria of iMCD.
• Archival and/or baseline incisional/excisional biopsy for retrospective central histologic confirmation of iMCD.
• CDCNRC-defined disease progression on or after prior treatment with siltuximab at 11 mg/kg q3w without unacceptable toxicity within 12 weeks between the last dose of siltuximab and the date of signed patient informed consent form (ICF).
• At least 1 measurable abnormal lymph node mass that is ≥1 cm in its longest transverse diameter as assessed by computerized tomography (CT) scan that has not been previously irradiated.
• Elevated (>10 mg/L) and rising serum CRP in the absence of additional iMCD treatment.
• Evidence of at least an additional one of the following laboratory or clinical signs of iMCD per international, evidence-based consensus diagnostic criteria for HIV or HHV 8-negative iMCD:
• Anemia, thrombocytopenia, hypoalbuminemia, renal dysfunction, or polyclonal hypergammaglobulinemia.
• Constitutional symptoms (night sweats, fever (>38°C), weight loss, or fatigue (CTCAE lymphoma B-symptoms score ≥2), large spleen and/or liver, fluid accumulation, eruptive cherry hemangiomatosis/violaceous papules, or lymphocytic interstitial pneumonitis.
• Adequate clinical laboratory measurements within 3 weeks prior to study entry in all parameters below:
• Absolute neutrophil count ≥1.0 × 109/L, hemoglobin <17 g/dL, and platelets ≥50 × 109/L without transfusion, hematopoietic growth factors, or both for >7 days prior to measurement.
• AST, ALT, total bilirubin, and alkaline phosphatase ≤5 × ULN.
• Fasting cholesterol <300 mg/dL and fasting triglyceride <400 mg/dL.
• Age ≥12 years.

You may not qualify if…

• Documentation of HIV or HHV-8 infection or presence of other infection-related disorders that resemble clinical or histological features of iMCD
• Diagnosis of any malignant/benign lymphoproliferative disorders
• Diagnosis of autoimmune/autoinflammatory disease
• Treatment with corticosteroids (prednisone dose-equivalent >1 mg/kg/day) within 7 days prior to study entry.
• History of solid organ transplant, allogeneic bone marrow transplant, or allogeneic peripheral blood stem cell transplant.
• Previous malignancy with the following exceptions:
• Past malignancy with treatment that was completed at least 2 years before signing informed consent and the patient has no evidence of disease, or
• Concurrent malignancy that is clinically stable and does not require tumor-directed treatment (eg, nonmelanoma skin cancer and carcinoma in situ)

Where it is running

• Edward W. Sparrow Hospital — Lansing, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.